In 2018, Spark Therapeutics will work toward the continued expansion of its recently approved Luxturna treatment, company co-founder and CEO Jeffrey D. Marrazzo said in a presentation at the 36th Annual J.P. Morgan Healthcare Conference.
With Luxturna’s FDA approval, Marrazzo described 2017 as a “trailblazing year for us at Spark.” Luxturna (voretigene neparvovec-rzyl) is a gene therapy approved to treat children and adults with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Spark Therapeutics ended 2017 with $539 million in cash,
Uncategorized